Ace Pharmaceuticals B.V.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ace Pharmaceuticals B.V. - overview
Established
1990
Location
-, -, Netherlands
Primary Industry
Pharmaceuticals
About
Based in the Netherlands, and founded in 1990, Ace Pharmaceuticals B. V. , also known as Ace, operates as a manufacturing firm that manufactures pharmaceutical products for clinical research applications. In 2021, Gilde Buy Out Partners, Gilde Healthcare, and Quadrum Capital acquired Ace Pharmaceuticals BV.
As of 2023, the company’s CEO is Drik Groen. Ace Pharmaceuticals develops, markets, and sells pharmaceutical products. The company’s product line includes Acecort® hydrocortisone, a film-coated tablet; A-CQ 100® chloroquine, a tablet; A-QS 200® quinine sulfate dihydrate, a film-coated tablet; Acepurin® allopurinol, an infusion powder; Acipen®-V Phenoxymethyl Penicillin, a capsule; Hydrocortisone ACE, an acidic ear drop; and many more. The firm provides products and services through its subsidiaries: Ace Pharmacy, Ace Compounding BV, Ace Pharmaceuticals Belgium BV, and Ace Pharmaceuticals GmbH.
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.ace-pharm.nl
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.